Novartis Foundation showcases progress in leprosy elimination programs at 19th International Leprosy Congress
The Novartis Foundation and its partners will highlight progress in efforts toward accelerating the elimination of leprosy at the 19th International Leprosy Congress (ILC) held in Beijing, China from September 18 – 21, 2016. Updates in 11 abstracts on four Novartis Foundation-supported leprosy initiatives in low- and middle-income countries will be showcased in scientific sessions.
Abstracts presented at the ILC demonstrate progress on the key programs under the Novartis Foundation strategy toward zero transmission of leprosy. The strategy was launched in 2014 to prioritize early detection and treatment, contact tracing and preventative treatment, strengthening of surveillance systems to become action-oriented and developing tools for faster and earlier diagnosis.
Novartis Foundation-sponsored projects presented at ILC scientific sessions:
Cambodia Retrospective Active Case Finding project: recommendations for targeting high-priority districts in phase 2 (Abstract ILC4.2-052/8.5, September 19, 13:30 CST)
Accuracy of the Leprosy Alert Response Network and Surveillance (LEARNS) System of the Novartis Foundation and Philippine Department of Health - National Leprosy Control Program (ILC4.2-025/8.3, September 19, 13:30 CST)
Criteria for a developing a PCR test (Abstract 47.1, September 20, 10:30 CST)
Emerging evidence from the Leprosy Post-Exposure Prophylaxis project (Abstract ILC4.3-012/17.1, September 20, 13:30 CST)
An interim report on the operational feasibility of leprosy post-exposure prophylaxis in Dadra and Nagar Haveli, India (Abstract ILC4.3-014/17.2, September 20, 13:30 CST)
Comparison of implementation aspects of Leprosy Post-Exposure Prophylaxis in India, Nepal and Indonesia (Abstract ILC4.3-022/17.3, September 20, 13:30 CST)
Negotiating and implementing the Leprosy Post-Exposure Prophylaxis project in the centralized health service of the Union of Myanmar (Abstract ILC4.3-011/17.4, September 20, 13:30 CST)
LPEP and implementation experiences from Nepal (Abstract ILC4.3-009/17.5, September 20, 13:30 CST)
Modeling the long term impact of additional interventions on the new case detection rate of leprosy in three endemic countries and regions (Abstract ILC4.3-007/17.6, September 20, 13:30 CST)
Delivering leprosy post-exposure prophylaxis in a remote area: a case of Lingat Village, Maluku, Indonesia (Abstract ILC4.3-017/25.6, September 20, 15:30 CST)
Distribution of leprosy post-exposure prophylaxis through extended contact-tracing with self-screening approach in Sumenep District, Indonesia (Abstract ILC4.3-018/25.8, September 20, 15:30 CST)
Novartis and the Novartis Foundation have a long-term commitment to leprosy treatment and control. Since 2000, Novartis has donated more than 56 million blister packs valued at approximately USD 90 million through the World Health Organization (WHO), helping to treat more than six million leprosy patients worldwide.